Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Rocket Pharmaceuticals (NasdaqGM:RCKT) with a Outperform recommendation. Analyst Price Forecast Suggests 381.87% Upside As of ...

Rocket’s lentiviral (LV) vector-based hematology portfolio consists ... and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction ...

China’s nuclear strategy is shifting, with PLARF expanding its arsenal and adopting a Launch on Warning posture. India must ...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat ...

BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report released on Wednesday morning, Ratings reports. The brokerage issued an outperform ...

Choose from Rocket Ship Launch Pad stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection ...

Bill Maher returned to the topic of the Best Picture Oscar winner Anora on Friday's Real Time With Bill Maher.

A stunning blue and white spiral spotted in skies across Europe late Monday was created by frozen fuel tumbling from a SpaceX ...

Credit: Rocket Lab HOUSTON — Rocket Lab says the first launch of its Neutron rocket remains planned for 2025 after a recent research report concluded it could slip to as late as 2027.